Want to join the conversation?
Healthcare company $BAX said it has received marketing authorization from the authorities in the UK and Denmark for NUMETA G13E 300 ml, a parenteral nutrition (PN) product. NUMETA G13E is indicated for PN administration for neonatal patients when oral or enteral nutrition is impossible, insufficient or contraindicated.
Still in yesterday’s $PZZA shock. I thought everyone had more pizza this football season!!
$TSLA stock downgraded to sell from hold by brokerage firm CFRA Research. However, the firm lifted the price target by $35 to $240.
$LB shares have plummeted after a disappointing quarter.